The Food and Drug Administration (FDA) has certified a new Covid-19 antibody drug for people with high-risk health problems or allergies who can’t get protection from vaccination. The antibody-drug is authorised for long-term protection against the Covid-19 virus rather than short-term treatment.
People who can benefit from the antibody drug are cancer patients, organ transplant recipients and patients taking immune-suppressing drugs for diseases like rheumatoid arthritis. Health experts say that approximately 2 to 3 per cent of the population of the US is into that group.
- Kotak Mahindra Bank Shares Crash 13% Post RBI Action
- Nestle India Joins Hands With Dr Reddy for Nutritional Health Solutions
- Inox Wind Shares Traded 9% Higher On Board Proposal For Bonus Shares Issuance
- Nestle India Stocks Gained 3% on Q4FY24 Business and Financial Updates
- Rail Vikas Nigam Shares Gain 3% on Securing Project Worth Rs 239 Crore
The FDA and other health officials have highlighted that antibody drugs are not a replacement for vaccines, the most effective, long-lasting and protection again coronavirus. Antibody drugs are hard to manufacture and cost over $1,000 per dose compared with regular vaccines, usually under $30 per dose.